* Rigel Pharmaceuticals Inc RIGL.OQ reported quarterly
adjusted
earnings of 70 cents per share for the quarter ended September
30, higher than the same quarter last year, when the company
reported EPS of -30 cents. The mean expectation of six analysts
for the quarter was for earnings of 6 cents per share. Wall
Street expected results to range from -21 cents to 32 cents per
share.
* Revenue rose 96.6% to $55.31 million from a year ago;
analysts
expected $41.93 million.
* Rigel Pharmaceuticals Inc's reported EPS for the quarter
was 70
cents.
* The company reported quarterly net income of $12.42
million.
* Rigel Pharmaceuticals Inc shares had fallen by 6.8% this
quarter and gained 4.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is "hold."
Wall Street's median 12-month price target for Rigel
Pharmaceuticals Inc is $16.00
This summary was machine generated from LSEG data November 8 at
05:12 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.06 0.70 Beat
Jun. 30 2024 -0.29 -0.06 Beat
Mar. 31 2024 -0.29 -0.50 Missed
Dec. 31 2023 -0.30 0.00 Beat